- Report
- April 2024
- 270 Pages
Global
From €4562EUR$5,000USD£3,923GBP
- Report
- January 2023
- 131 Pages
Global
From €2281EUR$2,500USD£1,961GBP
- Report
- October 2019
Global
From €2299EUR$2,520USD£1,977GBP
€2554EUR$2,800USD£2,197GBP
- Report
- April 2023
- 305 Pages
Global
From €3193EUR$3,500USD£2,746GBP
€4562EUR$5,000USD£3,923GBP
- Report
- April 2025
- 182 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- April 2024
- 180 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- January 2024
- 182 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- August 2022
- 111 Pages
Global
From €4333EUR$4,750USD£3,727GBP
- Report
- January 2022
- 120 Pages
Global
From €4333EUR$4,750USD£3,727GBP
- Report
- January 2024
- 200 Pages
Global
From €3786EUR$4,150USD£3,256GBP
- Report
- August 2023
- 145 Pages
Global
From €2874EUR$3,150USD£2,471GBP
- Report
- January 2023
- 154 Pages
Global
From €4060EUR$4,450USD£3,491GBP
- Report
- May 2023
- 147 Pages
Global
From €4515EUR$4,949USD£3,883GBP
- Report
- April 2023
- 140 Pages
Global
From €4515EUR$4,949USD£3,883GBP
- Report
- November 2021
- 545 Pages
Global
From €3649EUR$4,000USD£3,138GBP
- Report
- November 2021
- 365 Pages
Global
From €3193EUR$3,500USD£2,746GBP
- Report
- November 2021
- 802 Pages
Global
From €4562EUR$5,000USD£3,923GBP
- Report
- October 2023
- 428 Pages
Global
From €3257EUR$3,570USD£2,801GBP
- Report
- April 2022
- 262 Pages
Global
From €3153EUR$3,456USD£2,711GBP
- Book
- September 2024
- 304 Pages

The Germ Line market is a subset of the biotechnology industry that focuses on the development of germ line therapies. These therapies involve the manipulation of the genetic material of an organism, typically through genetic engineering, to produce a desired outcome. Germ line therapies are used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Germ line therapies are typically developed through the use of gene editing techniques, such as CRISPR-Cas9, which allow for precise manipulation of genetic material. This technology has enabled researchers to develop treatments for a variety of diseases, including those caused by genetic mutations.
The Germ Line market is a rapidly growing sector of the biotechnology industry, with many companies investing in the development of new therapies. Companies such as Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics are leading the way in the development of germ line therapies. Additionally, many pharmaceutical companies, such as Novartis and Pfizer, are investing in the development of germ line therapies. Show Less Read more